Functional polymorphisms of macrophage migration inhibitory factor as predictors of morbidity and mortality of pneumococcal meningitis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 13, 2016, Pages 3597-3602

  Savva, Athina ^a,c   Brouwer, Matthijs C ^b   Roger, Thierry ^a   Serón, Mercedes Valls ^b   Le Roy, Didier ^a   Ferwerda, Bart ^b   Van Der Ende, Arie ^b   Bochud, Pierre Yves ^a   Van De Beek, Diederik ^b   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR; ISOMERASE; MICROSATELLITE DNA; MIF PROTEIN, HUMAN; NEUTRALIZING ANTIBODY;

ADULT; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BLOOD; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; GENE LOCUS; GENETIC MARKER; GENOTYPE; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; LUCIFERASE ASSAY; MACROPHAGE MIGRATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PNEUMOCOCCAL MENINGITIS; PRIORITY JOURNAL; PROMOTER REGION; SEPSIS; SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; UPREGULATION; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CASE CONTROL STUDY; CELL LINE; DISEASE MODEL; EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MIDDLE AGED; NETHERLANDS; PATHOGENICITY; PROSPECTIVE STUDY;

ADULT; AGED; ANIMALS; ANTIBODIES, NEUTRALIZING; CASE-CONTROL STUDIES; CELL LINE; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED BALB C; MICROSATELLITE REPEATS; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE;

EID: 84962129248     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1520727113     Document Type: Article

References (59)

1. Lozano R, et al. (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380(9859):2095-2128.
2. Brouwer MC, et al. (2009) Host genetic susceptibility to pneumococcal and meningococcal disease: A systematic review and meta-Analysis. Lancet Infect Dis 9(1):31-44.
3. Brouwer MC, Tunkel AR, van de Beek D (2010) Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev 23(3):467-492.
4. Thigpen MC, et al.; Emerging Infections Programs Network (2011) Bacterial meningitis in the United States, 1998-2007. N Engl J Med 364(21):2016-2025.
5. Edmond K, et al. (2010) Global and regional risk of disabling sequelae from bacterial meningitis: A systematic review and meta-Analysis. Lancet Infect Dis 10(5):317-328.
6. Heckenberg SG, Brouwer MC, van der Ende A, Hensen EF, van de Beek D (2012) Hearing loss in adults surviving pneumococcal meningitis is associated with otitis and pneumococcal serotype. Clin Microbiol Infect 18(9):849-855.
7. Jit M (2010) The risk of sequelae due to pneumococcal meningitis in high-income countries: A systematic review and meta-Analysis. J Infect 61(2):114-124.
8. Casanova JL, Abel L, Quintana-Murci L (2011) Human TLRs and IL-1Rs in host defense: Natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 29:447-491.
9. Kasanmoentalib ES, Brouwer MC, van de Beek D (2013) Update on bacterial meningitis: Epidemiology, trials and genetic association studies. Curr Opin Neurol 26(3): 282-288.
10. Chapman SJ, et al. (2006) PTPN22 and invasive bacterial disease. Nat Genet 38(5): 499-500.
11. Roy S, et al.; Oxford Pneumoccocal Surveillance Group (2002) MBL genotype and risk of invasive pneumococcal disease: A case-control study. Lancet 359(9317):1569-1573.
12. Khor CC, et al. (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39(4):523-528.
13. Chapman SJ, et al. (2007) IkappaB genetic polymorphisms and invasive pneumococcal disease. Am J Respir Crit Care Med 176(2):181-187.
14. Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayedtype hypersensitivity. Science 153(3731):80-82.
15. David JR (1966) Delayed hypersensitivity in vitro: Its mediation by cell-free substances formed by lymphoid cell-Antigen interaction. Proc Natl Acad Sci USA 56(1):72-77.
16. Calandra T, et al. (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377(6544):68-71.
17. Mitchell RA, et al. (2002) Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response. Proc Natl Acad Sci USA 99(1):345-350.
18. Roger T, Chanson AL, Knaup-Reymond M, Calandra T (2005) Macrophage migration inhibitory factor promotes innate immune responses by suppressing glucocorticoidinduced expression of mitogen-Activated protein kinase phosphatase-1. Eur J Immunol 35(12):3405-3413.
19. Roger T, David J, Glauser MP, Calandra T (2001) MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414(6866):920-924.
20. Bucala R (2013) MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol 33(Suppl 1):S72-S78.
21. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: A regulator of innate immunity. Nat Rev Immunol 3(10):791-800.
22. Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (2002) Macrophage migration inhibitory factor (MIF): Mechanisms of action and role in disease. Microbes Infect 4(4): 449-460.
23. Baugh JA, et al. (2002) A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis. Genes Immun 3(3):170-176.
24. Donn RP, Shelley E, Ollier WE, Thomson W; British Paediatric Rheumatology Study Group (2001) A novel 5′-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 44(8):1782-1785.
25. Renner P, Roger T, Calandra T (2005) Macrophage migration inhibitory factor: Gene polymorphisms and susceptibility to inflammatory diseases. Clin Infect Dis 41(Suppl 7): S513-S519.
26. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D (2011) Pathogenesis and pathophysiology of pneumococcal meningitis. Clin Microbiol Rev 24(3):557-591.
27. Bernhagen J, et al. (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13(5):587-596.
28. Doernberg S, et al. (2011) Association of macrophage migration inhibitory factor (MIF) polymorphisms with risk of meningitis from Streptococcus pneumoniae. Cytokine 53(3):292-294.
29. Ostergaard C, Benfield T (2009) Macrophage migration inhibitory factor in cerebrospinal fluid from patients with central nervous system infection. Crit Care 13(3):R101.
30. Awandare GA, et al. (2009) MIF (macrophage migration inhibitory factor) promoter polymorphisms and susceptibility to severe malarial anemia. J Infect Dis 200(4):629-637.
31. Lehmann LE, et al. (2009) A MIF haplotype is associated with the outcome of patients with severe sepsis: A case control study. J Transl Med 7:100.
32. Yende S, et al. (2009) The influence of macrophage migration inhibitory factor gene polymorphisms on outcome from community-Acquired pneumonia. FASEB J 23(8): 2403-2411.
33. Renner P, et al. (2012) A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal disease. FASEB J 26(2):907-916.
34. Das R, et al. (2014) Functional polymorphisms in the gene encoding macrophage migration inhibitory factor are associated with Gram-negative bacteremia in older adults. J Infect Dis 209(5):764-768.
35. Bochud PY, Bochud M, Telenti A, Calandra T (2007) Innate immunogenetics: A tool for exploring new frontiers of host defence. Lancet Infect Dis 7(8):531-542.
36. Chapman SJ, Hill AV (2012) Human genetic susceptibility to infectious disease. Nat Rev Genet 13(3):175-188.
37. Calandra T, et al. (2000) Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6(2):164-170.
38. Beishuizen A, Thijs LG, Haanen C, Vermes I (2001) Macrophage migration inhibitory factor and hypothalamo-pituitary-Adrenal function during critical illness. J Clin Endocrinol Metab 86(6):2811-2816.
39. Emonts M, et al. (2007) Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis. Clin Infect Dis 44(10):1321-1328.
40. Sprong T, et al. (2007) Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock 27(5):482-487.
41. Arjona A, et al. (2007) Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J Clin Invest 117(10):3059-3066.
42. Lazear HM, et al. (2015) Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci Transl Med 7(284):284ra59.
43. Calandra T, Spiegel LA, Metz CN, Bucala R (1998) Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Grampositive bacteria. Proc Natl Acad Sci USA 95(19):11383-11388.
44. Roger T, et al. (2013) Macrophage migration inhibitory factor deficiency is associated with impaired killing of gram-negative bacteria by macrophages and increased susceptibility to Klebsiella pneumoniae sepsis. J Infect Dis 207(2):331-339.
45. Das R, et al. (2014) Macrophage migration inhibitory factor promotes clearance of pneumococcal colonization. J Immunol 193(2):764-772.
46. Bernhagen J, et al. (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365(6448):756-759.
47. Lehmann LE, et al. (2001) Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27(8):1412-1415.
48. Roger T, Glauser MP, Calandra T (2001) Macrophage migration inhibitory factor (MIF) modulates innate immune responses induced by endotoxin and Gram-negative bacteria. J Endotoxin Res 7(6):456-460.
49. Calandra T, Froidevaux C, Martin C, Roger T (2003) Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis. J Infect Dis 187:(Suppl 2):S385-S390.
50. Weiser JN, et al. (2015) Macrophage migration Inhibitory factor is detrimental in pneumococcal pneumonia and a target for therapeutic immunomodulation. J Infect Dis 212(10):1677-1682.
51. Kerschbaumer RJ, et al. (2012) Neutralization of macrophage migration inhibitory factor (MIF) by fully human antibodies correlates with their specificity for the β-sheet structure of MIF. J Biol Chem 287(10):7446-7455.
52. Roger T, et al. (2011) Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 117(4):1205-1217.
53. Lugrin J, et al. (2009) Histone deacetylase inhibitors repress macrophage migration inhibitory factor (MIF) expression by targeting MIF gene transcription through a local chromatin deacetylation. Biochim Biophys Acta 1793(11):1749-1758.
54. Woehrl B, et al. (2011) Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. J Clin Invest 121(10): 3943-3953.
55. Little J, et al. (2002) Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 156(4):300-310.
56. Jennett B, Bond M (1975) Assessment of outcome after severe brain damage. Lancet 1(7905):480-484.
57. van de Beek D, et al. (2004) Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 351(18):1849-1859.
58. Roger T, Ding X, Chanson AL, Renner P, Calandra T (2007) Regulation of constitutive and microbial pathogen-induced human macrophage migration inhibitory factor (MIF) gene expression. Eur J Immunol 37(12):3509-3521.
59. Delaloye J, et al. (2009) Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 5(6):e1000480.